Live Breaking News & Updates on Michael Wolff Jensen

Stay updated with breaking news from Michael wolff jensen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ascendis Pharma A/S : Form 6-K - MarketScreener

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

. ....

New Zealand , United Kingdom , United States , Republic Of , United Arab Emirates , Redwood City , Hong Kong , Saudi Arabia , Republic Of China , Taiwan General , Great Britain , Sandoz Gmb , Ascendis Pharma , Michael Wolff Jensen , Biopartners Gmb , Eli Lilly , Novo Nordisk , Somatropin Biopartners , Securities Exchange , Clinical Development In Adults , Company Unaudited Condensed Consolidated Interim Financial , International Accounting Standards Board , Other Development , Commission File Number , Merck Kga , Pharmaceuticals Co Ltd ,

Form 6-K Ascendis Pharma A/S For: Dec 05

Form 6-K Ascendis Pharma A/S For: Dec 05
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Ascendis Pharma , Michael Wolff Jensen , K Ascendis Pharma , Drug Administration , Securities Exchange , Commission File Number , File Number , Exact Name , Its Charter , Registration Numbers , Securities Exchange Act , Michael Wolff , Vice President , Chief Legal ,

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
– Advances Vision 3×3 to extend global clinical and commercial reach –
COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing.
“Our relationship with VISEN is a key element of our Vision 3×3 strategy to extend the global reach of our TransCon endocrinology rare disease product candidates and improve patients’ lives around the world,” said Jan Mikkelsen, President and CEO at Ascendis Pharma. “Since VISEN’s inception in 2018, the company has made significant progress on its clinical activities in Greater China, which we believe will enable us to get our products to pat ....

Hong Kong , New Jersey , United States , Palo Alto , Redwood City , Baden Wuberg , Ascendis Pharma , Jan Mikkelsen , Michael Wolff Jensen , Exchange Commission , Technology Platform , Advances Vision , Greater China , Senior Vice President , Chief Legal Officer , Vivo Capital , Sofinnova Ventures , Ascendi Vision , Annual Report , ஹாங் காங் , புதியது ஜெர்சி , ஒன்றுபட்டது மாநிலங்களில் , பாலோ ஆல்டோ , ரெட்வுட் நகரம் , ஜான் மைக்கேல்சன் , மைக்கேல் ஓநாய் ஜென்சன் ,